BIOGEN INC (BIIB)
US09062X1037 - Common Stock
BIIB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 577 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
BIIB had a positive operating cash flow in the past year.
In the past 5 years BIIB has always been profitable.
In the past 5 years BIIB always reported a positive cash flow from operatings.
1.2 Ratios
BIIB has a better Return On Assets (4.39%) than 95.64% of its industry peers.
BIIB has a Return On Equity of 7.67%. This is amongst the best in the industry. BIIB outperforms 95.82% of its industry peers.
With an excellent Return On Invested Capital value of 7.81%, BIIB belongs to the best of the industry, outperforming 95.30% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BIIB is below the industry average of 14.68%.
The last Return On Invested Capital (7.81%) for BIIB is well below the 3 year average (11.97%), which needs to be investigated, but indicates that BIIB had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.67% | ||
| ROIC | 7.81% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)11.97%
ROIC(5y)17.09%
1.3 Margins
Looking at the Profit Margin, with a value of 12.07%, BIIB belongs to the top of the industry, outperforming 96.52% of the companies in the same industry.
In the last couple of years the Profit Margin of BIIB has declined.
The Operating Margin of BIIB (21.96%) is better than 97.21% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB has a better Gross Margin (75.03%) than 85.19% of its industry peers.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.96% | ||
| PM (TTM) | 12.07% | ||
| GM | 75.03% |
OM growth 3Y-17.42%
OM growth 5Y-15.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.99%
GM growth 5Y-3.01%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
Compared to 1 year ago, BIIB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.49 indicates that BIIB is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.49, BIIB is doing good in the industry, outperforming 75.26% of the companies in the same industry.
BIIB has a debt to FCF ratio of 5.09. This is a neutral value as BIIB would need 5.09 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.09, BIIB belongs to the top of the industry, outperforming 95.12% of the companies in the same industry.
A Debt/Equity ratio of 0.41 indicates that BIIB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.41, BIIB is not doing good in the industry: 72.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | 5.09 | ||
| Altman-Z | 3.49 |
ROIC/WACC0.75
WACC10.36%
2.3 Liquidity
BIIB has a Current Ratio of 2.10. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.10, BIIB is doing worse than 75.96% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that BIIB should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.32, BIIB is not doing good in the industry: 82.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.1 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
The earnings per share for BIIB have decreased strongly by -12.14% in the last year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.49% yearly.
The Revenue has decreased by -4.37% in the past year.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -6.07% on average per year.
EPS 1Y (TTM)-12.14%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%7.94%
Revenue 1Y (TTM)-4.37%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-7%
3.2 Future
BIIB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.06% yearly.
BIIB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.55% yearly.
EPS Next Y5.68%
EPS Next 2Y8.43%
EPS Next 3Y9.45%
EPS Next 5Y9.06%
Revenue Next Year-4.1%
Revenue Next 2Y-1.9%
Revenue Next 3Y0.02%
Revenue Next 5Y1.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 13.76, BIIB is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 98.61% of the companies listed in the same industry.
BIIB's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.41.
BIIB is valuated reasonably with a Price/Forward Earnings ratio of 11.91.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.59, BIIB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.76 | ||
| Fwd PE | 11.91 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 96.69% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.94 | ||
| EV/EBITDA | 14.55 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIIB does not grow enough to justify the current Price/Earnings ratio.
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.42
PEG (5Y)N/A
EPS Next 2Y8.43%
EPS Next 3Y9.45%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
NASDAQ:BIIB (7/26/2024, 7:19:04 PM)
After market: 211.17 0 (0%)211.17
-16.27 (-7.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.76 | ||
| Fwd PE | 11.91 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.96% | ||
| PM (TTM) | 12.07% | ||
| GM | 75.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.1 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-12.14%
EPS 3Y-22.83%
EPS 5Y
EPS Q2Q%
EPS Next Y5.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.37%
Revenue growth 3Y-9.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y